Autoinjectable testosterone now available for the first time
The US Food and Drug Administration (FDA) has approved testosterone enanthate (Xyosted, Antares Pharma) subcutaneous injection (50 mg, 75 mg, and 100 mg) for testosterone replacement therapy in men diagnosed with conditions associated with a deficiency or absence of endogenous testosterone. It is the first FDA-approved subcutaneous testosterone enanthate product for once-weekly self-administration using a disposable autoinjector.
To continue reading this article
Continue reading your article with a eMediNexus account.